News Updates

More Articles Back to Article

Consortium to develop pan-cancer blood assay

Under the Dutch-Swiss consortium Mainline, Lausanne University Hospital, PamGene International and Alithea Genomics will collaborate on a pan-cancer blood assay to predict the safety and efficacy of immune checkpoint inhibitor treatment. The consortium, which has Eurostars grant funding worth $1.1 million, will develop a transcriptomics biomarker panel and a pan-cancer predictive kinome profile and will use blood samples from eligible patients for validation and training of the model. 360Dx (tiered subscription model) (1/17)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!